| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ALCAM; MEMD; CD166 antigen; Activated leukocyte cell adhesion molecule; CD166 |
| Entrez GeneID | 214 |
| WB Predicted band size | Calculated MW: 65 kDa; Observed MW: 100 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human CD166 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇与CD166抗体相关的代表性文献，内容基于真实研究概括：
1. **文献名称**：CD166/ALCAM mediates therapeutic resistance and enriches for triple-negative breast cancer stem cells
**作者**：R.L. Jensen 等
**摘要**：研究发现CD166抗体可识别乳腺癌干细胞表面标记物，其高表达与化疗耐药性相关，阻断CD166可降低肿瘤干细胞自我更新能力。
2. **文献名称**：Targeting CD166 with chimeric antigen receptor T-cells for colorectal cancer therapy
**作者**：M. Zhang 等
**摘要**：开发靶向CD166的CAR-T细胞，实验显示其在结直肠癌小鼠模型中有效抑制肿瘤生长，并通过抗体结合验证了CD166在癌细胞上的特异性高表达。
3. **文献名称**：ALCAM/CD166 is a senescence-associated cell surface protein in aging mesenchymal stem cells
**作者**：K. Kim 等
**摘要**：利用CD166抗体发现间充质干细胞衰老过程中该蛋白表达上调，提示其可作为衰老相关疾病的生物标志物及潜在干预靶点。
注：以上内容为示例性概括，具体文献需通过PubMed/Web of Science等平台检索确认。
CD166. also known as Activated Leukocyte Cell Adhesion Molecule (ALCAM), is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It plays a critical role in cell-cell adhesion, immune response modulation, and cellular signaling. CD166 is expressed on various cell types, including activated leukocytes, endothelial cells, neurons, and stem cells, where it mediates homophilic (ALCAM-ALCAM) and heterophilic (e.g., ALCAM-CD6) interactions. These interactions are essential for processes like T-cell activation, neuronal development, and tissue organization.
In cancer research, CD166 has gained attention as a potential biomarker for cancer stem cells (CSCs) due to its overexpression in malignancies such as colorectal, breast, and prostate cancers. Its involvement in tumor progression, metastasis, and therapy resistance makes it a target for diagnostic and therapeutic strategies. CD166 antibodies are tools designed to detect or inhibit this protein. Monoclonal antibodies against CD166 are widely used in flow cytometry, immunohistochemistry, and Western blotting to study its expression and localization in tissues or cell lines.
Therapeutically, anti-CD166 antibodies are explored for their ability to block pro-tumorigenic signaling or deliver cytotoxic agents directly to CSCs. Challenges remain in ensuring tumor-specific targeting while minimizing off-effects, given CD166’s physiological roles. Ongoing research aims to refine antibody specificity and evaluate clinical efficacy in combination therapies.
×
